SEC Info - Acorda Therapeutics Inc - ‘8-K’ for 10/4/19

SEC Info℠

Home

Help

Please Sign In

Acorda Therapeutics Inc – ‘8-K’ for 10/4/19

On: Friday, 10/4/19, at 8:00am ET · For: 10/4/19 · Accession #: 1564590-19-36439 · File #: 1-31938

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/04/19  Acorda Therapeutics Inc           8-K:8      10/04/19   10:152K                                   ActiveDisclosure/FA

Current Report — Form 8-K — Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     29K 
 5: R1          Document and Entity Information                     HTML     47K 
10: XML         IDEA XML File -- Filing Summary                      XML     11K 
 7: XML         XBRL Instance -- acor-8k_20191004_htm                XML     14K 
 9: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 3: EX-101.LAB  XBRL Labels -- acor-20191004_lab                     XML     56K 
 4: EX-101.PRE  XBRL Presentations -- acor-20191004_pre              XML     34K 
 2: EX-101.SCH  XBRL Schema -- acor-20191004                         XSD     19K 
 8: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    19K 
 6: ZIP         XBRL Zipped Folder -- 0001564590-19-036439-xbrl      Zip      9K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C: C: C: C: C:

i false i ACORDA THERAPEUTICS INC i 0001008848 0001008848 2019-10-04 2019-10-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): i October 4, 2019

Acorda Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

i Delaware	i 001-31938	i 13-3831168
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

i 420 Saw Mill River Road, i Ardsley, i NY		i 10502
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: i (914) i 347-4300

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

i Common Stock (Par Value $0.001)

i ACOR

i Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01Other Events

Acorda Therapeutics, Inc. (the “Company”) is providing an update on managed care access for INBRIJA™ (levodopa inhalation powder).

Since the Company’s second quarter 2019 conference call on August 1, 2019, it has signed additional agreements related to INBRIJA formulary placement at both the national and regional levels.

As a result, INBRIJA is now available in the U.S. without the need for a medical exception for approximately 66% of commercial and approximately 25% of Medicare plan lives.

INBRIJA was approved by the U.S. Food and Drug Administration on December 21, 2018 for the intermittent treatment of OFF episodes (also known as OFF periods) in people with Parkinson’s disease treated with carbidopa/levodopa.

The Company intends to provide additional INBRIJA launch updates on its third quarter 2019 conference call scheduled for Monday, November 4, 2019.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Acorda Therapeutics, Inc.

October 4, 2019	By:	/s/ *David Lawrence*
		Name: David Lawrence
		Title: Chief, Business Operations and Principal Accounting Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

	11/4/19	8-K
Filed on / For Period end:	10/4/19
	8/1/19	8-K
	12/21/18	4, 4/A, 8-K
		List all Filings

↑Top

Filing Submission 0001564590-19-036439 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)